Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Soleno Therapeutics to Participate in Upcoming November Conferences

globenewswire.com
SLNO The company's participation in investor conferences suggests a neutral sentiment as it indicates an effort to inform investors about the company's progress.

REDWOOD CITY, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it will participate in the following investor conferences in November:

Guggenheim Securities Healthcare Innovation Conference

Presentation Date: Tuesday, November 11, 2025 at 9:00 AM ET

Presentation Format: Fireside Chat

Webcast: Here

Stifel 2025 Healthcare Conference

Presentation Date: Wednesday, November 12, 2025 at 8:40 AM ET

Presentation Format: Fireside Chat

Webcast: Here

Jefferies London Healthcare Conference

Presentation Date: Tuesday, November 18, 2025 at 5:00 PM GMT

Presentation Format: Presentation

Webcast: Here

Replays of the events will be available in the Investors section on the Company’s website at www.soleno.life.

About Soleno Therapeutics, Inc.

Soleno is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company’s first commercial product, VYKAT XR™ (diazoxide choline) extended-release tablets, formerly known as DCCR, is a once-daily oral treatment for hyperphagia in adults and children 4 years of age and older with Prader-Willi syndrome. For more information, please visit www.soleno.life.

Corporate Contact:

Brian Ritchie

LifeSci Advisors, LLC

212-915-2578